Aligos Therapeutics, Inc.

NasdaqCM:ALGS 株式レポート

時価総額：US$53.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Aligos Therapeutics マネジメント

マネジメント 基準チェック /34

Aligos Therapeutics'の CEO はLarry Blattで、 Feb2018年に任命され、 の在任期間は 6.33年です。 の年間総報酬は$ 1.34Mで、 43.7%給与と56.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.75%を直接所有しており、その価値は$ 1.01M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と5.8年です。

主要情報

Larry Blatt

最高経営責任者

US$1.3m

報酬総額

CEO給与比率43.7%
CEO在任期間6.7yrs
CEOの所有権1.4%
経営陣の平均在職期間6.2yrs
取締役会の平均在任期間3.5yrs

経営陣の近況

Recent updates

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Jul 31
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Jul 16
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

May 24
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24
Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01
We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16
What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study

Oct 30

CEO報酬分析

Aligos Therapeutics の収益と比較して、Larry Blatt の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$76m

Mar 31 2024n/an/a

-US$100m

Dec 31 2023US$1mUS$587k

-US$88m

Sep 30 2023n/an/a

-US$82m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$83m

Dec 31 2022US$2mUS$549k

-US$96m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$126m

Mar 31 2022n/an/a

-US$136m

Dec 31 2021US$873kUS$549k

-US$128m

Sep 30 2021n/an/a

-US$125m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$116m

Dec 31 2020US$7mUS$493k

-US$109m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$62m

Dec 31 2019US$674kUS$475k

-US$52m

報酬と市場: Larryの 総報酬 ($USD 1.34M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Larryの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Larry Blatt (62 yo)

6.7yrs

在職期間

US$1,344,458

報酬

Dr. Lawrence M. Blatt, also known as Larry, Ph D., MBA, has been Chief Executive Officer and Director at Aligos Therapeutics, Inc. since February 2018 and also has been its Chairman of the Board since June...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Lawrence Blatt
CEO, President & Chairman of the Board6.7yrsUS$1.34m1.39%
$ 741.1k
Julian Symons
Executive VP & Chief Scientific Officer6.4yrsUS$836.32k0.26%
$ 135.9k
Lesley Calhoun
Executive VP & CFO4.3yrsデータなしデータなし
Kristina Engeseth
VP and Head of People & Culture2.8yrsデータなしデータなし
Sushmita Chanda
Executive Vice President & Chief Development Officer6.2yrsデータなしデータなし
David Smith
Executive VP & Head of Chemical Operations6.2yrsデータなしデータなし
Tse-I Lin
VP of Early Compound Development & Belgian Site Head2.8yrsデータなしデータなし

6.2yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: ALGSの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称ポジション在職期間報酬所有権
Lawrence Blatt
CEO, President & Chairman of the Board6.7yrsUS$1.34m1.39%
$ 741.1k
Carole Nuechterlein
Independent Director6.2yrsUS$12.90kデータなし
K. Hirth
Independent Director6.2yrsUS$60.40k0.039%
$ 20.5k
James Scopa
Independent Director3.5yrsUS$67.90k0.12%
$ 63.1k
Heather Preston
Independent Directorless than a yearデータなしデータなし
Margarita Chavez
Independent Directorless than a yearデータなしデータなし
Bridget Martell
Independent Director2.9yrsUS$52.90kデータなし

3.5yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: ALGSの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。